The sad story of Vioxx, and what we should learn from it.

@article{Karha2004TheSS,
  title={The sad story of Vioxx, and what we should learn from it.},
  author={J. Karha and E. Topol},
  journal={Cleveland Clinic journal of medicine},
  year={2004},
  volume={71 12},
  pages={
          933-4, 936, 938-9
        }
}
Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is specific for cyclo-oxygenase-2 (COX-2); it is therefore termed a COX-2 inhibitor, or coxib. To tell the story of how it came to be withdrawn, we must start in 1999 when the Food and Drug Administration (FDA) approved it for the relief of arthritis symptoms. The approval was based on data from trials lasting 3 to 6 months and involving patients at low risk for cardiovascular illness. 
34 Citations
Chapter 8 – Safety and Toxicology
  • 1
Cellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms
  • K. Sakane, C. J. Monteiro, +4 authors K. Moraes
  • Medicine
  • Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • 2014
  • 7
  • PDF
Patients centred pharmacovigilance
  • PDF
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
Failing the public health--rofecoxib, Merck, and the FDA.
  • E. Topol
  • Medicine
  • The New England journal of medicine
  • 2004
  • 582
  • PDF
Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
  • 30
...
1
2
3
...